NCT02837328View on ClinicalTrials.gov

Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

September 15, 2017

Study Completion Date

September 15, 2017

Conditions
Premature Atrial Contraction
Interventions
DRUG

Oral Magnesium Supplement

400 mg Magnesium Citrate 1x daily for 12 weeks

DRUG

Placebo

Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks

Trial Locations (1)

55454

University of Minnesota - Twin Cities, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02837328 - Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias | Biotech Hunter | Biotech Hunter